Porter J P, Reid I A, Said S I, Ganong W F
Am J Physiol. 1982 Sep;243(3):F306-10. doi: 10.1152/ajprenal.1982.243.3.F306.
Vasoactive intestinal peptide (VIP) increased plasma renin activity (PRA) in pentobarbital-anesthetized dogs. A 15-min infusion of VIP directly into the renal artery at a dose of 33 ng . kg-1 min-1 increased renin secretion rate from 1,461 +/- 393 to 5,769 +/- 1,794 ng ANG I . ml-1 . 3 h-1 . min-1, and increased PRA from 19.2 +/- 2.3 to 29.2 +/- 4.7 ng ANG I . ml-1 . 3 h-1. Renal blood flow and creatinine clearance were also increased, whereas plasma potassium concentration and diastolic blood pressure decreased. There was no change in sodium or potassium excretion. When administered intravenously, 33 and 13 ng . kg-1 . min-1 VIP increased PRA. A dose of 3.3 ng . kg-1 . min-1 failed to increased PRA when given intravenously but produced a significant increase in PRA from 22.8 +/- 8.1 to 40.5 +/- 19.4 ng ANG I . ml-1 . 3 h-1 when infused into the renal artery. This increase occurred without any change in plasma potassium concentration or blood pressure. Renin secretion was increased by a two- to threefold increase in plasma VIP; comparable increases in plasma VIP have been reported to be produced by various experimental procedures. The data indicate that VIP increases renin secretion. The peptide appears to act directly on the kidney and may act directly on the juxtaglomerular cells.
血管活性肠肽（VIP）可增加戊巴比妥麻醉犬的血浆肾素活性（PRA）。以33 ng·kg⁻¹·min⁻¹的剂量直接向肾动脉内输注15分钟的VIP，可使肾素分泌率从1,461±393增加至5,769±1,794 ng血管紧张素I·ml⁻¹·3 h⁻¹·min⁻¹，并使PRA从19.2±2.3增加至29.2±4.7 ng血管紧张素I·ml⁻¹·3 h⁻¹。肾血流量和肌酐清除率也增加，而血浆钾浓度和舒张压降低。钠或钾排泄无变化。静脉注射时，33和13 ng·kg⁻¹·min⁻¹的VIP可增加PRA。静脉注射3.3 ng·kg⁻¹·min⁻¹的剂量未能增加PRA，但当注入肾动脉时可使PRA从22.8±8.1显著增加至40.5±19.4 ng血管紧张素I·ml⁻¹·3 h⁻¹。这种增加在血浆钾浓度或血压无任何变化的情况下发生。血浆VIP增加两到三倍可使肾素分泌增加；据报道，各种实验程序可使血浆VIP产生类似的增加。数据表明VIP可增加肾素分泌。该肽似乎直接作用于肾脏，可能直接作用于肾小球旁细胞。
